[{"id":"f1019130-1357-4f9c-93ac-a373d891ebad","acronym":"ReDiscover","url":"https://clinicaltrials.gov/study/NCT05216432","created_at":"2022-02-05T18:28:00.435Z","updated_at":"2025-02-25T17:37:34.946Z","phase":"Phase 1","brief_title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer","source_id_and_acronym":"NCT05216432 - ReDiscover","lead_sponsor":"Relay Therapeutics, Inc.","biomarkers":" HER-2 • PIK3CA • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • zovegalisib (RLY-2608) • atirmociclib (PF-07220060)"],"overall_status":"Recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"}]